RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Chemical engineers design way to manufacture peptides in mere hours

Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018.

19 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

TAF proteins may serve as potential targets to fight ovarian cancer

In the complex genomic and molecular conspiracy that gives rise to ovarian cancer, what if researchers have been missing a whole set of suspects because they've been hiding in plain sight?

17 Mar 2014

Hepatitis C patients with ITPA gene variants exhibit lower risk of relapse after treatment

More than 100 million humans around the world are infected with hepatitis C virus. The infection gives rise to chronic liver inflammation, which may result in reduced liver function, liver cirrhosis and liver cancer.

14 Mar 2014

Researchers identify new player in onset and progression of heart failure

A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.

13 Mar 2014

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

11 Mar 2014

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.

11 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Three longtime allies have joined forces to create the new Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

7 Mar 2014

Study to understand how bisphenol-A may promote breast cancer growth

UT Arlington biochemists say their newly published study brings researchers a step closer to understanding how the commonly used synthetic compound bisphenol-A, or BPA, may promote breast cancer growth.

6 Mar 2014

New findings shed light on how gene mutation causes motor neurone disease

Researchers have discovered a mechanism that may explain how a recently discovered mutation causes two devastating neurological diseases.

6 Mar 2014

Inflammation and stress combine in bipolar and schizophrenia subtypes

Researchers have found that some individuals with bipolar disorder or schizophrenia have combined stress response and immune dysfunctions.

6 Mar 2014

New findings shed light on how gene mutation causes motor neurone disease

Researchers have discovered a mechanism that may explain how a recently discovered mutation causes two devastating neurological diseases.

6 Mar 2014

Scientists reveal how a genetic code variation results in devastating brain diseases

New findings reveal how a mutation, a change in the genetic code that causes neurodegeneration, alters the shape of DNA, making cells more vulnerable to stress and more likely to die.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Small-molecule drug effective in protecting nonhuman primates from lethal Marburg virus

For the first time, scientists have demonstrated the effectiveness of a small-molecule drug in protecting nonhuman primates from the lethal Marburg virus. Their work, published online in the journal Nature, is the result of a continuing collaboration between Army scientists and industry partners that also shows promise for treating a broad range of other viral diseases.

5 Mar 2014

Blocking myoferlin gene can reduce breast cancer cell migration

New research suggests that a protein only recently linked to cancer has a significant effect on the risk that breast cancer will spread, and that lowering the protein's level in cell cultures and mice reduces chances for the disease to extend beyond the initial tumor.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

4 Mar 2014

Researchers discover that carbohydrates serve as identifiers for cancer cells

Researchers at New York University and the University of Texas at Austin have discovered that carbohydrates serve as identifiers for cancer cells. Their findings, which appear in the journal Proceedings of the National Academy of Sciences, show how these molecules may serve as signals for cancer and explain what's going on inside these cells, pointing to new ways in which sugars function as a looking glass into the workings of their underlying structures.

4 Mar 2014

RNA News and Research

Further Reading

Chemical engineers design way to manufacture peptides in mere hours

Trovagene reports net loss of $1 million for fourth quarter 2013

TAF proteins may serve as potential targets to fight ovarian cancer

Hepatitis C patients with ITPA gene variants exhibit lower risk of relapse after treatment

Researchers identify new player in onset and progression of heart failure

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Exosome Diagnostics closes Series B financing round with the raising of $27 million

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Study to understand how bisphenol-A may promote breast cancer growth

New findings shed light on how gene mutation causes motor neurone disease

Inflammation and stress combine in bipolar and schizophrenia subtypes

New findings shed light on how gene mutation causes motor neurone disease

Scientists reveal how a genetic code variation results in devastating brain diseases

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Small-molecule drug effective in protecting nonhuman primates from lethal Marburg virus

Blocking myoferlin gene can reduce breast cancer cell migration

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

Researchers discover that carbohydrates serve as identifiers for cancer cells

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News